Theratechnologies
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Theratechnologies sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Theratechnologies: 7 sponsored US clinical trials, none currently recruiting.
Theratechnologies sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multi-Antiviral Resistance, with 1 trials.
Upper-quartile sponsor footprint
Theratechnologies sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
TH1902 in Patients With Advanced Solid Tumors
NCT04706962
The Visceral Adiposity Measurement and Observation Study
NCT05383456
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
NCT01579695
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
NCT01591902
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
NCT00608023
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00123253
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
How the Theratechnologies archive is shaped
7 indexed studies, none listed as recruiting (0% open); 3 completed (43%).
Phase mix: 3 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Multi-Antiviral Resistance (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Theratechnologies: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Theratechnologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Theratechnologies page
7 registered trials is a research-attention snapshot, not an endorsement of Theratechnologies or any single study.
- None of Theratechnologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Multi-Antiviral Resistance is the condition Theratechnologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multi-Antiviral Resistance trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Theratechnologies pipeline card: 7 registered trials from official public datasets.Report a data error.